MYELOFIBROSIS

This study tests a vaccine designed to protect people who have had a stem cell transplant from a common virus called CMV. The virus can cause serious illness in those with weak immune systems. The vaccine uses a harmless virus to teach the body to fight CMV, aiming to reduce infe…

This study tests a vaccine called Triplex to prevent cytomegalovirus (CMV) infection in adults who have received a stem cell transplant. CMV can cause serious illness in people with weakened immune systems. The vaccine uses harmless pieces of CMV DNA to help the body build immuni…

This study tests whether adding pelabresib to the standard drug ruxolitinib works better than ruxolitinib alone for people with myelofibrosis, a rare bone marrow disorder. About 430 adults who have not had prior JAK inhibitor treatment will participate. The main goal is to see if…

This early-phase study tests an experimental drug called INCB057643, given alone or with the standard drug ruxolitinib, in adults with myelofibrosis or other advanced blood cancers. The main goals are to check safety and see if the drug can reduce spleen size, which is a key sign…

This study tested a stem cell transplant using blood stem cells from a half-matched (haploidentical) donor for people with blood cancers like leukemia and lymphoma. The goal was to see how many patients survived and had successful engraftment by 100 days and one year after transp…

This study gives continued access to itacitinib for 18 patients who were already benefiting from the drug in earlier trials. It covers three serious conditions: myelofibrosis (a bone marrow disorder), bronchiolitis obliterans after lung transplant, and chronic graft-versus-host d…

This study tests a new drug, imetelstat, against the best current treatments for people with a serious bone marrow cancer called myelofibrosis. Participants have a high-risk form of the disease that no longer responds to standard therapy. The goal is to see if imetelstat helps pe…

This early-phase study tests a new treatment for people whose blood cancer (like AML or MDS) has returned after a donor stem cell transplant. The treatment combines a special type of donor immune cell infusion with an immunotherapy drug called ipilimumab. The main goal is to find…

This study tests whether adding the experimental drug veliparib to standard chemotherapy (topotecan and carboplatin) helps people with advanced myeloproliferative disorders, acute myeloid leukemia, or chronic myelomonocytic leukemia. About 25 adults took part. The goal was to see…

This early-phase study tests the safety of combining three drugs—navitoclax, venetoclax, and decitabine—for people with advanced myeloid blood cancers like acute myeloid leukemia and myelofibrosis. The goal is to find the safest effective dose and see how well the combination wor…

This early-stage study tests a new antibody drug called Hu8F4 in 72 people with advanced blood cancers like leukemia and myelodysplastic syndrome. The main goals are to find the safest dose and check for side effects. The drug works by targeting a protein on cancer cells to stop …

This study tests an experimental drug (BMS-986158) alone or combined with standard therapies (ruxolitinib or fedratinib) in about 216 adults with intermediate- or high-risk myelofibrosis, a rare bone marrow cancer. The goal is to check safety and whether the drug can shrink an en…

This study tests whether a lower dose of the drug cyclophosphamide, given after a stem cell transplant from a partially matched donor, can reduce serious infections while still preventing graft-versus-host disease (a condition where donor cells attack the patient's body). About 3…

This early-stage study tests a new drug called IOA-244 in about 210 adults with advanced or metastatic cancers, including solid tumors, lymphoma, lung cancer, melanoma, and myelofibrosis. The main goal is to check if the drug is safe and tolerable, and to see if it can boost the …

This study tests a drug called selinexor against the doctor's choice of treatment for people with myelofibrosis, a rare bone marrow disorder. Participants must have already tried a JAK inhibitor for at least 6 months. The main goal is to see if selinexor can shrink the spleen and…

This study tests whether adding the drug selinexor to the standard treatment ruxolitinib works better than ruxolitinib alone for people with myelofibrosis, a rare bone marrow cancer. About 353 adults with moderate-to-high risk disease who have not had prior treatment will take pa…

This study compares a stem cell transplant to the best available non-transplant treatments for people with high-risk myelofibrosis, a serious bone marrow cancer. About 90 participants will choose which treatment they prefer, and researchers will track survival and quality of life…

This study tests whether combining two drugs, ruxolitinib and thalidomide, can shrink the cancer and improve symptoms in people with myelofibrosis, a rare bone marrow disorder. About 30 adults with the disease, including those who have tried other treatments, will receive the com…

This early-phase trial tests whether vaccinating stem cell donors against cytomegalovirus (CMV) can help protect the transplant recipient from CMV infection. About 34 people with blood cancers receiving a donor stem cell transplant will have their donors vaccinated before donatio…

This study follows about 40 people with intermediate- or high-risk myelofibrosis who have already been taking gecacitinib in earlier studies. Researchers will collect bone marrow and blood samples once a year to see if the disease grade or certain gene mutations change over time.…